Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study. Issue 6 (June 2021)

• Record Type: Journal Article
• Authors: Lora-Tamayo, Jaime; Maestro, Guillermo; Lalueza, Antonio; Rubio-Rivas, Manuel; Villarreal Paul, Gracia; Arnalich Fernández, Francisco; Beato Pérez, José Luis; Vargas Núñez, Juan Antonio; Llorente Barrio, Mónica; Lumbreras Bermejo, Carlos
• Is Part Of: Journal of infection. Volume 82:Issue 6(2021)
• Page Start: 276
• Page End: 316
• Publication Date: 2021-06
• Subjects: Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2021.02.011
• Languages: English
• ISSNs: 0163-4453

Abstract

Highlights: This is the largest study assessing the efficacy of LPV/r against SARS-CoV-2. The overall use of LPV/r was not associated with lower mortality in CoVID19 patients. The early use of LPV/r (median 5 days) showed no benefit either.